Glimilife-M1 Tablet PR

Glimilife-M1 Tablet PR is prescribed to manage blood glucose levels in individuals diagnosed with type 2 diabetes

Glimilife-M1 Tablet PR belongs to the class of oral hypoglycaemics, which are used to treat diabetes by lowering blood sugar levels. It achieves this by increasing the amount of insulin released by the pancreas and improving the body's insulin utilization. By doing so, it helps to regulate blood glucose levels more effectively.

The maximum effects of this medicine may take up to 2 weeks of regular dosing to develop, with peak effects seen within 23 hours for immediate release forms and 4 to 8 hours for slow release forms.

Patients prescribed it should adhere to their healthcare provider's recommendations regarding dosage and duration of treatment.

It is crucial to report any persistent symptoms or adverse effects promptly.